Overview
Study Evaluating Multiple Ascending Dose in Schizophrenia Patients
Status:
Terminated
Terminated
Trial end date:
2008-03-01
2008-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a randomized, inpatient, ascending multiple dose study to assess safety and tolerability of SLV-313 SR tablets administered orally to subjects with schizophrenia and schizoaffective disorder.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of PfizerCollaborator:
Solvay Pharmaceuticals
Criteria
Inclusion Criteria:- Men, aged 18-50 years old
- Women, aged 18-50 years old
Exclusion Criteria:
- Non-lactating women, aged 18-50 years old
- Non-pregnant women, aged 18-50 years old